Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™. (SCOUT)
Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for Symptomatic Chronic Functional Tricuspid Regurgitation
Sponsor: Mitralign, Inc.
Listed as NCT02574650, this NA trial focuses on Chronic Symptomatic Functional Tricuspid Regurgitation and Heart Valve Disease and remains ongoing. Sponsored by Mitralign, Inc., it has been updated 10 times since 2015, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Nov 2019 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2019 [monthly]
Recruiting NA
-
Nov 2017 — Jun 2018 [monthly]
Recruiting NA
-
Aug 2017 — Nov 2017 [monthly]
Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mitralign, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .